Listed by the USPTO as SHAMEEM, GOLAM M
Tech Center 1600 • Art Units: 1621 1622 1626 1629 1674
This examiner grants 87% of resolved cases
SHAMEEM, GOLAM M is assigned to Tech Center 1600 and Art Unit 1621, with 898 resolved cases. The allowance rate is 86.7%, and the median time to allowance is 688 days. The interview lift is 15.9%, showing a positive but limited association between interviews and allowance outcomes. No art unit benchmark is supplied, so the figures support examiner-specific planning rather than a unit-wide comparison.
The leading companies are University of Florida Research Foundation Inc., THE GENERAL HOSPITAL Corporation, and Pfizer Inc. The principal firms are ALSTON & BIRD LLP, AMIN WASSERMAN GURNANI LLP, and BELL & ASSOCIATES. Applicants can plan around a favorable allowance result and a comparatively shorter median timing within this profile. Interviews remain useful, but the modest lift suggests that strong application preparation and focused written prosecution should remain central.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18268216 | Facile Purification of Cannabinoid Acids | Non-Final OA | Individual inventor |
| 18842118 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18762951 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | Non-Final OA | The General Hospital Corporation |
| 18719456 | COMBINATION THERAPIES AND USES FOR TREATING CANCER | Non-Final OA | Pfizer Inc. |
| 18949084 | THERAPEUTIC COMPOUNDS | Non-Final OA | Sanofi |
| 18859011 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Non-Final OA | Treeline Biosciences, Inc. |
| 18763849 | SYNERGIES OF 1- BETA-CARYOPHYLLENE, CANNABIDIOL AND TRIBUTYRIN; 2- RETINYL PALMITATE, BETA-CARYOPHYLLENE AND CANNABIDIOL; 3- RETINYL PALMITATE AND BETA-CARYOPHYLLENE IN CONTROLING INFLAMMATION, METABOLIC HEALTH, INSULIN SENSITIVITY/ GLYCEMIC - GLUCOSE UPTAKE & MANAGEMENT, AND FATTY LIVER/ NAFLD | Non-Final OA | FLG Sciences, LLC |
| 18842111 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Non-Final OA | Trustlife Global Inc. |
| 18762851 | PHARMACEUTICAL COMPOSITIONS FOR USE IN REDUCING HYPERPIGMENTATION | Non-Final OA | Caliway Biopharmaceuticals Co., Ltd. |
| 18714605 | Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (PCpEV) | Non-Final OA | Evexys Biotech Oy |
| 18708662 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | Non-Final OA | ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (A.F.M.) |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | Non-Final OA | NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD |
| 18696722 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | Non-Final OA | HALDA THERAPEUTICS OPCO, INC. |
| 18687692 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | Non-Final OA | Pretzel Therapeutics, Inc. |
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | Non-Final OA | Seagen Inc. |
| 18537947 | THIOL ISOMERASES INHIBITORS AND USE THEREOF | Non-Final OA | WESTERN NEW ENGLAND UNIVERSITY |
| 17694902 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | Final Rejection | BIAL - PORTELA & CA, S.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy86.7% of resolved applications examined by Golam M Shameem were allowed (898 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +15.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Golam M Shameem took 688 days on average from filing to allowance.
Golam M Shameem examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
